Test Albuvirtide in Experienced Patients (TALENT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02369965 |
|
Recruitment Status :
Completed
First Posted : February 24, 2015
Last Update Posted : October 6, 2021
|
Sponsor:
Frontier Biotechnologies Inc.
Information provided by (Responsible Party):
Frontier Biotechnologies Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections AIDS | Drug: albuvirtide Drug: lopinavir-ritonavir Drug: tenofovir Drug: lamivudine | Phase 3 |
This was a 48-week, multi-center, open-label, randomized and controlled, non-inferiority phase 3 clinical trial to evaluate the safety and efficacy of albuvirtide combined with LPV/r in HIV-1 infected patients who failed their first-line ART and had HIV-1 RNA levels ≥ 1000 copies/mL at screening.
The trial was conducted in 12 sites in China. Subjects meeting inclusion criteria were randomized in a 1:1 ratio to ABT group and NRTI group, in which the ABT group received albuvirtide and LPV/r combination therapy, and NRTI group received the standard 3-drug regimen of LPV/r + Lamivudine (3TC) + Tenofovir (TDF). If TDF was used in the previous regimen or genotypic resistance histories showed primary mutation to TDF, zidovudine (AZT) or abacavir (ABC) would be used. Albuvirtide was given by weekly intravenous infusion and LPV/r was given twice daily orally. A total of 418 subjects were randomized, of whom 401 received at least one treatment.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 418 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of Albuvirtide for Injection Combined With LPV/r for Treatment of HIV-1-Infected Patients Failed First-line Antiretroviral Therapy |
| Actual Study Start Date : | February 19, 2014 |
| Actual Primary Completion Date : | April 2, 2018 |
| Actual Study Completion Date : | April 2, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: albuvirtide, lopinavir-ritonavir
albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
|
Drug: albuvirtide
albuvirtide 320mg administered intravenously once a week
Other Name: ABT Drug: lopinavir-ritonavir lopinavir-ritonavir 400/100mg administered orally twice daily
Other Names:
|
|
Active Comparator: lopinavir-ritonavir,tenofovir,lamivudine
lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
|
Drug: lopinavir-ritonavir
lopinavir-ritonavir 400/100mg administered orally twice daily
Other Names:
Drug: tenofovir tenofovir 300mg administered orally once daily
Other Name: TDF Drug: lamivudine lamivudine 300mg administered orally once daily
Other Name: 3TC |
Primary Outcome Measures :
- Percentage of participants of virological suppression at Week 48 [ Time Frame: Through Week 48 ]Percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48
Secondary Outcome Measures :
- Changes of viral load [ Time Frame: Baseline to Week 48 ]Changes of HIV-1 RNA relative to baseline at Week 48
- Percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 [ Time Frame: Through Week 48 ]Percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48
- Changes of CD4 cell count [ Time Frame: Baseline to Week 48 ]Changes of CD4 cell count relative to baseline at Week 48
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 60 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 16-60 years old, male or female.
- Those who meet the Diagnostic Criteria of AIDS and HIV Infection, the Health Industry Standard of the People's Republic of China (WS 293-2008).
- Those who have been undergoing antiretroviral treatment with nucleosides and non-nucleoside reverse transcriptase inhibitors (NRTIs+NNRTIs) for at least 6 months.
- HIV-RNA ≥ 1000 copies/mL.
- Those who have no serious hepatic or renal functional impairment and other parameters are generally in the normal ranges according to the comprehensive physical examinations (including general physical examination, routine blood and urine tests, blood chemistry tests, ECG, etc.).
- The subjects should have a full understanding of the objective, nature, methods of the trial and the possible reactions. He/She should participate in the trial voluntarily and should sign the informed consent form.
Exclusion Criteria:
- Those who are in an acute stage of infection, or have suffered from AIDS-related diseases (e.g. opportunistic infections or malignant tumors, etc.) at enrollment; or have suffered from opportunistic infections within 3 months prior to enrollment and the conditions have not reached a stable state within 2 weeks prior to enrollment.
- Those who have used protease inhibitors or HIV fusion inhibitors for antiretroviral treatment, and who have participated in HIV vaccine clinical trials or have participated in other drug trials within recent 3 months.
- Those who have been co-administered antiviral treatment for hepatitis.
- Those whose screening test results meet one of the following: hemoglobin < 9 g/dL, WBC count <2×109/L, neutrophil count < 1×109/L, PLT count < 75×109/L, transaminase > 3×ULN, total bilirubin > 2×ULN, creatinine > 1×ULN, serum creatine phosphokinase > 2×ULN.
- Those with allergic constitution or known allergic to ingredients of the investigational drug or ART drugs prescribed in the protocol.
- Currently suffering from serious chronic diseases, metabolic diseases (such as diabetes mellitus), neurological and psychiatric disorders.
- Patients with hemophilia A or B.
- Those with suspected or confirmed history of alcohol or drug abuse.
- Pregnant or lactating women; or women of childbearing age who refuse to take contraceptive measures during the trial.
- Those for whom the possibility of being enrolled is low according to the judgment of the investigator (e.g. weak physical condition, poor compliance, etc.).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02369965
Locations
| China, Beijing | |
| 302 Hospital People's Liberation Army Of China | |
| Beijing, Beijing, China | |
| Beijing Ditan Hospital, Capital Medical University | |
| Beijing, Beijing, China | |
| Beijing Youan Hospital, Capital medical university | |
| Beijing, Beijing, China | |
| China, Guangdong | |
| Guangzhou Eighth People's Hospital | |
| Guangzhou, Guangdong, China | |
| The Third People'S Hospital Of Shenzhen | |
| Shenzhen, Guangdong, China | |
| China, Henan | |
| Henan Infectious Disease Hospital | |
| Zhengzhou, Henan, China | |
| China, Hunan | |
| The First Hospital of Changsha | |
| Changsha, Hunan, China | |
| The Second Xiangya Hospital of Central South University | |
| Changsha, Hunan, China | |
| China, Shanghai | |
| Shanghai Public Health Clinical Center | |
| Shanghai, Shanghai, China | |
| China, Shanxi | |
| Tangdu Hospital, Fourth Military Medical University | |
| Xi'an, Shanxi, China | |
| China, Zhejiang | |
| Affiliated Hangzhou Xixi Hospital,Zhejiang University School Of Medicine | |
| Hangzhou, Zhejiang, China | |
| The First Affiliated Hospital Zhejiang University School Of Medicine | |
| Hangzhou, Zhejiang, China | |
Sponsors and Collaborators
Frontier Biotechnologies Inc.
Investigators
| Study Director: | Dong Xie | Frontier Biotechnologies Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Frontier Biotechnologies Inc. |
| ClinicalTrials.gov Identifier: | NCT02369965 |
| Other Study ID Numbers: |
FB-ABWT-Ⅲ-301 ChiCTR-TRC-14004276 ( Registry Identifier: Chinese Clinical Trial Registry ) |
| First Posted: | February 24, 2015 Key Record Dates |
| Last Update Posted: | October 6, 2021 |
| Last Verified: | September 2021 |
Keywords provided by Frontier Biotechnologies Inc.:
|
HIV-1 AIDS Albuvirtide Treatment-experienced Fusion inhibitor |
Additional relevant MeSH terms:
|
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Tenofovir |
Lamivudine HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |